.Nature Medicine, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medicine conjugate (ADC) tisotumab vedotin resulted in boosted progression-free and also general survival, resulting in FDA commendation as well as a new procedure choice for clients.